Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Jon C. Ogg | Feb 10, 2014 at 3:20 PM EST

Gilead Going to $90, or $110

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is rising on Monday after two analysts made positive calls on the biotech giant. As…

Jon C. Ogg | Feb 10, 2014 at 8:25 AM EST

Top Analyst Upgrades and Downgrades: Fairway Group, J.P. Morgan, Red Robin, Vodafone, More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on is Monday, February 10,…

Jon C. Ogg | Feb 4, 2014 at 4:29 PM EST

Despite Size, Gilead Keeps Growing and Growing

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is the biggest biotech company in America, and it is one of the top performers…

cgblaine22 | Jan 29, 2014 at 12:10 PM EST

Why Caution Is Prevailing in Biotechs Into and After Earnings

Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences…

Trey Thoelcke | Jan 29, 2014 at 8:15 AM EST

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large…

Jon C. Ogg | Jan 8, 2014 at 8:10 AM EST

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going…

Trey Thoelcke | Jan 2, 2014 at 8:20 AM EST

UBS Top High Conviction Stock Picks for 2014

The U.S. equity strategy team at UBS has a positive view on stocks heading into 2014, particularly technology, financials and…

Jon C. Ogg | Dec 30, 2013 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, December 30, 2013.

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Dec 18, 2013 at 8:20 AM EST

Piper Jaffray Top Stocks to Buy for 2014

courtesy of Apple Inc.Like most firms that we cover on Wall Street, Piper Jaffray has updated its top names to…

Lee Jackson | Dec 11, 2013 at 9:00 AM EST

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing…

Jon C. Ogg | Dec 10, 2013 at 4:04 PM EST

Big Insider Selling at Gilead

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) has been on fire, so much that two insiders decided to stuff their holiday stockings…

Jon C. Ogg | Nov 22, 2013 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Gilead, Gogo, Micron, Target, Windstream and More

ThinkstockThe DJIA has finally closed above 16,000 for the first time ever. With a light holiday week coming up and…

Jon C. Ogg | Nov 21, 2013 at 7:25 AM EST

Solid Biotech Stocks With the Best Revenue Growth for 2014

ThinkstockAny time investors look for companies growing sales the most, one area that almost always stands out is the up…

Jon C. Ogg | Nov 19, 2013 at 11:50 AM EST

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies…

1 … 38 39 40 41 42 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Gilead Going to $90, or $110

Top Analyst Upgrades and Downgrades: Fairway Group, J.P. Morgan, Red Robin, Vodafone, More

Despite Size, Gilead Keeps Growing and Growing

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

UBS Top High Conviction Stock Picks for 2014

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Piper Jaffray Top Stocks to Buy for 2014

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

Big Insider Selling at Gilead

Top Analyst Upgrades and Downgrades: Gilead, Gogo, Micron, Target, Windstream and More

Solid Biotech Stocks With the Best Revenue Growth for 2014

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Gilead Sciences : GILD

All Gilead Sciences Articles

Gilead Going to $90, or $110

Top Analyst Upgrades and Downgrades: Fairway Group, J.P. Morgan, Red Robin, Vodafone, More

Despite Size, Gilead Keeps Growing and Growing

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

UBS Top High Conviction Stock Picks for 2014

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Piper Jaffray Top Stocks to Buy for 2014

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

Big Insider Selling at Gilead

Top Analyst Upgrades and Downgrades: Gilead, Gogo, Micron, Target, Windstream and More

Solid Biotech Stocks With the Best Revenue Growth for 2014

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s